Study of Blood Samples From Newborns With Down Syndrome

Not Recruiting

Trial ID: NCT00959283

Purpose

This research study is looking at blood samples from newborns with Down syndrome. Studying the genes expressed in samples of blood from patients with Down syndrome may help doctors identify biomarkers related to cancer.

Official Title

Biology Study of Transient Myeloproliferative Disorder (TMD) in Children With Down Syndrome (DS)

Stanford Investigator(s)

Eligibility


Inclusion Criteria:

   - Diagnosis of transient myeloproliferative disorder (TMD) at < 90 days of age and
   meeting 1 of the following criteria:

      - A diagnosis of Down syndrome or Down syndrome mosaicism AND non-erythroid and
      non-lymphoid blasts (any amount) in the peripheral blood verified with a second
      sample

         - Patients with typical physical characteristics of Down syndrome are allowed
         before cytogenetic or FISH confirmation of the diagnosis

      - Trisomy 21-positive leukemic blasts documented by biopsy of any organ (including
      > 5% non-erythroid/non-lymphoid blasts documented by bone marrow aspirate or
      biopsy)

         - Infants with isolated trisomy 21 positivity identified only in the leukemic
         blasts are allowed

   - Institutional immunophenotype characterization is required for study enrollment

Intervention(s):

other: pharmacological study

other: Diagnostic Laboratory Biomarker Analysis

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061

New Trial Alerts

Receive email alerts when trials open to patients.